Curcumin and Evodiamine Combo Reduces Lung Injury
A Nanjing University team reported in Targetome that paired compounds limited lung damage in mice with inflammation linked to severe empyema.
Updated on Nov. 16, 2026 in Asthma

Researchers led by Xudong Wu's team at Nanjing University published a study in Targetome on November 5, 2026, reporting that combined curcumin and evodiamine treatment reduced signaling through MAPK8 and JAK2 enzymes. In mice, the combination brought inflammatory markers close to control levels.
Why it matters
Inflammation in severe empyema can damage the barrier that keeps fluid from leaking into the lung's air sacs, so compounds that reduce that damage could point toward new supporting treatments. The findings remain at an early stage and do not yet establish clinical use.
The evidence comes from mouse experiments and cultured human lung cells, plus gene profiling from one patient's pleural fluid collected over three weeks. Whether these results hold in larger patient studies and live infection models has not yet been determined.
The players
Nanjing University
A major public research university in Nanjing, China, whose research team conducted the study.
The details
The team profiled small molecules and gene activity in pleural fluid from a patient with severe Klebsiella pneumoniae empyema. Mice given lipopolysaccharide were treated beforehand, and each compound reduced lung swelling and injury when given alone, with the combination doing more; curcumin preferentially stabilized MAPK8 and evodiamine modestly stabilized MAPK8 and JAK2 in cultured cells.
Timeline
Pleural fluid was collected over three weeks from one patient with severe empyema.
The study was published in Targetome on November 5, 2026.
Health Landscape
The work follows a network pharmacology approach that maps drug targets through gene-network analysis rather than single-pathway screening. It extends that method into severe bacterial empyema, a condition where treatment options for persistent inflammation remain limited.
For now, the findings do not change how empyema or severe lung infections are treated. Patients and clinicians should continue following established care, as any future treatment would require larger human trials and safety testing first.
The takeaway
Early laboratory findings can identify promising directions, but they require human trials before affecting care. Readers interested in respiratory health should track peer-reviewed follow-up work rather than treat the results as a clinical recommendation.
Further reading
Explore more on Asthma for related respiratory research.
Source note: This article includes information reported by Firstwordpharma.







